Ahmed Said Kadah

Ahmed Said Kadah

Auto-generated profile, based on publicly available information

Ahmed Said Kadah

Department of Dermatology, Faculty of Medicine for Girls, Al-Azhar University, New Damietta, Egypt

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2022 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
ANAhmed Hassan Nouh
Ahmed Hassan Nouh
AKAhmed S. Kadah
Ahmed S. Kadah
MSMarwa Said
Marwa Said
Background Alopecia areata (AA) is an autoimmune disease that is represented as patches of hair loss, FractionalCo2 laser and Cryotherapy are used to stimulate hair growth in patients of AA. Aim evaluation of fractional co2 laser effect versus liquid nitrogen cryotherapy in the treatment of Alopecia Areata. Methods Eighty patients presented with patches of AA. The first group consisted of 40 patients was treated with fractional co2 laser, the second group also 40 patients was treated with cryotherapy. The efficacy of the treatment was statistically evaluated. Results A positive therapeutic response was noted in most patients By trichoscopy at the end of treatment, there was a decrease in exclamation mark hairs, yellow dots, black dots, broken hairs, and an increase in short vellus hair and circle hair of patients compared to baseline and control. No serious side effects were seen. Conclusion Fractional co2 laser and Liquid nitrogen cryotherapy is considered a promising, safe, and effective treatment modality with the better result with co2 laser

22 January 2023 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
ANAhmed Hassan Nouh
Ahmed Hassan Nouh
AEAhmed R. Elshahid
Ahmed R. Elshahid
AKAhmed S. Kadah
Ahmed S. Kadah
YZYoussef A. Zeyada
Youssef A. Zeyada
Background: Cutaneous lupus erythematosus is an umbrella term for a group of autoimmune connective tissue disorders affecting the skin. Discoid lupus erythematosus (DLE) is the chronic condition and most common form of cutaneous lupus erythematosus.Aims: Current therapies of DLE are challenging and not completely satisfactory, highly expensive, off‐label, or poorly available (like antimalarials due to COVID‐19 outbreaks). Nicotinamide, also called niacinamide, is a water‐soluble form of vitamin B3 (niacin). Its multiple effects let us think that nicotinamide could be a therapy for lupus‐associated skin lesions.Methods: We performed a prospective randomized double‐blind clinical trial on 60 subjects diagnosed with Discoid lupus erythematosus using topical Nicotinamide 2% and 4% preparations in form of cream and gel on skin and scalp lesions. Control group was included using only cream/gel base as placebo control.Results: Obtained data showed that topical Nicotinamide can be used for the treatment of DLE as adjuvant to other treatment regimens with good cosmetic results and minimal side effects. Topical 4% Nicotinamide is superior to 2% preparation in response but associated with a higher incidence of irritation.Conclusion: Topical Nicotinamide can be used for the treatment of DLE as an adjuvant to other treatment regimens with good cosmetic results and minimal side effects. Further trials with long‐term therapy, follow‐up period, and bigger sample sizes are required.

1 April 2025 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
MRMahmoud A. Rageh
Mahmoud A. Rageh
EREmad El Rewiny
Emad El Rewiny
AKAhmed S. Kadah
Ahmed S. Kadah
HZHazem B. Zakaria
Hazem B. Zakaria
MAMohamed Abdelshakour
Mohamed Abdelshakour
AMAhmed Abdelkader Mohamed
Ahmed Abdelkader Mohamed

30 November 2022 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
AEAhmed Rashad Elshahid
Ahmed Rashad Elshahid
AKAhmed Said Kadah
Ahmed Said Kadah
EHEman Abdellatif Hassan
Eman Abdellatif Hassan
MEMohamed L. Elsaie
Mohamed L. Elsaie

3 August 2022 in Dermatologic Therapy
Verified
Journal Article
Closed access
MEMohamed El‐Khalawany
Mohamed El‐Khalawany
ANAhmed Hassan Nouh
Ahmed Hassan Nouh
AKAhmed S. Kadah
Ahmed S. Kadah
MEMaged Elsheikh
Maged Elsheikh
MSMarwa Said
Marwa Said
To assess and evaluate the efficacy and safety of nicotinamide 4% topical formulation for the treatment of mild to moderate psoriasis. This study was conducted on 60 patients aged 18-65 years, with mild to moderate psoriasis vulgaris. Nicotinamide 4% in a cold cream base was used twice daily for 12 weeks. Nicotinamide 4% topical treatment shows satisfactory results, more in males than in females. Some patients report disturbing irritation (burning, itching, and redness) upon the usage of topical nicotinamide treatment and were advised to wash out the treated area after 1 h of cream application, which solved the issue. No other adverse effects of treatment were reported by patients during the study period. Unicentral base, a limited amount of sample size, and 12 weeks duration of therapy and follow-up period, which may not be sufficient to demonstrate the complete therapeutic properties and side effects of using nicotinamide as a long-term treatment for psoriasis. This study reveals statistically reliable evidence of the positive impact of topical 4% nicotinamide preparation used alone on the treatment of psoriasis with minimal side effects. Thus, we can conclude that topical nicotinamide preparation may be a good adjuvant to the current treatment regimens used alone or alternate currently used topical therapeutical regimens if used in combination.